Meeting slides
Suggested Readings

Atopic Dermatitis Overview and Pathogenesis

Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts.

Paternoster L, et al. J Allergy Clin Immunol. 2018:141(3):964-971.

Pathogenesis of atopic dermatitis.

Peng W, Novak N. Clin Exp Allergy. 2015;45(3):566-574.

Patient Burden and Comorbidities

The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis.

Chamlin SL, et at. Arch Pediatr Adolesc Med. 2005;159(8):745-750.

Association of atopic dermatitis and mental health outcomes across childhood: a longitudinal cohort study.

Kern C, et al. JAMA Dermatol. 2021;157(10):1200-1208.

‘His first word was “cream.”' The burden of treatment in paediatric atopic dermatitis—a mixed methods study.

O’Connor C, et al. Dermatol Ther. 2022;35(3):e15273.

Association between atopic dermatitis and suicidality: a systematic review and meta-analysis.

Sandhu JK, et al. JAMA Dermatol. 2019;155(2):178-187.

Increasing severity of early-onset atopic dermatitis, but not late-onset, associates with development of aeroallergen sensitization and allergic rhinitis in childhood.

Schoos AMM, et al. Allergy. 2022;77(4):1254-1262.

Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study.

Silverberg JI, et al. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2.

Comorbidities and the impact of atopic dermatitis.

Silverberg JI. Ann Allergy Asthma Immunol. 2019;123(2)144-151.

Management of Atopic Dermatitis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303.

Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial.

Blauvelt A, et al. JAMA Dermatol. 2021;157(9):1047-1055.

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.

Drucker AM, et al. Br J Dermatol. 2018;178(3):768-775.

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomized controlled phase 3 trials.

Guttman-Yassky E, et al. Lancet. 2021;397(10290):2151-2168.

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial.

Paller AS, et al. J Am Acad Dermatol. 2020;83(5):1282-1293.

Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial.

Silverberg JI, et al. JAMA Dermatol. 2020;156(8):863-873.

Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial.

Simpson EL, et al. JAMA Dermatol. 2020;156(1):44-56.

Linked Resources


ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.

Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2020;34(12):2717-2744.

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.

Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.

Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(6):850-878.

Patient Resources

International Eczema Council

Founded in late 2014, the International Eczema Council (IEC) is a global nonprofit organization led by dermatology experts on atopic dermatitis. The IEC is dedicated to increasing the understanding of atopic dermatitis and promoting its optimal management through research, education, and patient/family care.

Clinical Assessment Tools

Children’s Dermatology Life Quality Index (CDLQI)

CDLQI is 10-question patient-reported assessment tool designed to measure impact of any skin disease on the lives of children ages 4-16. (Lewis-Jones MS, Finlay AY. Br J Dermatol. 1995;132(6):942-949).

Patient-Oriented Eczema Measure (POEM)

The POEM is a patient-oriented, self-assessed measurement tool for monitoring aspects of atopic dermatitis in routine clinical practice or in the clinical trial setting. (Charman CR, et al. Arch Dermatol. 2004;140(12):1513-1519).

Related activities
0.50 CME/CE

Clearing the Way in Atopic Dermatitis

A Case-Based Update on Pediatric Patients

Faculty: Jacob P. Thyssen, MD, PhD, DmSci
Release: 07/01/2022
Expiration: 07/01/2023